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Previewsis their role in mature peripheral T cells?
The finding that coreceptors are recruited
after TCR signaling is initiated by Lck
phosphorylation explains why corecep-
tors are dispensable for T cell antigen
recognition. They may, however, play an
important modulatory role. For example,
coreceptors amplify TCR triggering,
thereby enabling recognition of low-
affinity or rare pMHC complexes.
Because affinity and abundance are
both important limiting factors in pMHC
recognition, this would broaden and
increase the sensitivity of the TCR reper-
toire. A second possible role arises from
the positive-feedback effect of corecep-
tor recruitment, whereby initial pMHC
binding sufficient to induce TCR-CD3phosphorylation is stabilized by corecep-
tor recruitment, which stabilizes the inter-
action and possibly enhances TCR-CD3
signaling. One effect of such a positive-
feedback mechanism would be to
improve the ability of T cells to discrimi-
nate between pMHC ligands with small
differences in affinity.REFERENCES
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In this issue of Immunity, Shaw et al. (2011) report that the NOD-RICK signaling axis is required for the acti-
vation of dendritic cells infiltrating the central nervous system, leading to reactivation of antigen-specific
T cells and autoimmune inflammation.The onset of autoimmunity is triggered by
both environmental and genetic elements,
contributing to the disruption of central
and peripheral tolerance, resulting in the
escape of autoreactive T cells fromnormal
selection. In this issue of Immunity, work
from the Kanneganti laboratory (Shaw
et al., 2011) has shed some light on the
mechanistic understanding how infec-
tions may trigger central nervous system
(CNS) autoimmune inflammation. Infec-
tious agents have long been suspected
to play a role in the activation of autoreac-
tive T cells, and recent studies have begun
to unravel a relationship between infec-
tions and certain chronic autoimmune
inflammatory diseases of the central
nervous system (CNS), including multiple
sclerosis (MS) (Getts and Miller, 2010).
Multiple sclerosis is an autoimmune
disease in which autoaggressive T lymph-
ocytes specifically reactive to myelinantigens are stimulated to initiate an
inflammatory response in the CNS,
leading to demyelination and subsequent
axonal injury. Importantly, peptidoglycan
(PGN), a major bacterial cell wall compo-
nent, has been detected in APCs located
in the brains of MS patients (Schrijver
et al., 2001). One salient feature of MS is
the relapsing and remitting nature of the
disease. Interestingly, bacterial infections
have been associated with the increased
risk of MS exacerbations. Therefore, the
mechanistic understanding of how infec-
tions might trigger CNS autoimmune
inflammatory response will probably offer
novel therapeutic strategies for the treat-
ment of MS patients.
Because PGN-containing APCs have
been detected in the brains of MS
patients, Shaw et al. (2011) set out to
determine the role of PGN-mediated
signaling in the CNS autoimmune inflam-matory response, which might yield
important mechanistic understanding
about the link between infections and MS
exacerbations. Nucleotide-binding and
oligomerization domain (NOD)-like recep-
tors (NLRs) NOD1 and NOD2 are the
known cytosolic sensors of fragments of
bacterial peptidoglycan, whereas Toll-like
receptor 2 (TLR2) detects peptidoglycan
at the cell surface. A dual-specificity pro-
tiein kinase RICK (receptor-interacting
protein-like interacting caspase-like
apoptosis regulatory protein kinase, also
called RIP2 or CARDIAK) functions down-
stream of NOD1 and NOD2 to mediate
NF-kB and mitogen-activated protein
kinase (MAPK) activation in a TLR-inde-
pendent manner (Park et al., 2007). By
using an animal model for CNS inflamma-
tion, experimental autoimmune encepha-
lomyelitis (EAE), Shaw et al. (2011)
attempted to investigate the relative34, January 28, 2011 ª2011 Elsevier Inc. 3
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Figure 1. Th1 and Th17 Cells in the Initiation and Effector Stages of EAE
Protein antigens (myelin components) and peptides are presented by antigen-presenting cells (APCs)
within lymph nodes to the neuroantigen-reactive T cells leading to Th1 and Th17 cell activation and prolif-
eration. TLR2 signaling in CD4+ T cells promotes Th17 cell proliferation. Th1 and Th17 cells then cross the
blood-brain barrier. Peptidoglycan-induced NOD-RICK signaling was found to be important for the ‘‘self-
activation’’ of CD11c+ dendritic cells and for their ability to restimulate T cells. The large numbers of acti-
vated Th1 and Th17 cells and other inflammatory cells (macrophages and microglia) subsequently
produce inflammatory mediators that act on oligodendrocytes and neurons, resulting in tissue destruction
including demyelination and eventually neurologic deficit.
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Previewsimportance of the NOD1 and NOD2-RICK
signaling axis versus TLR2 signaling in the
pathogenesis of PGN-dependent CNS
inflammation. They concluded that the
NOD-RICK pathway, but not TLR2, plays
a critical role in the activation of CNS-infil-
trating dendritic cells. These findings
suggest that PGN-dependent EAE
progression might be mediated through
the activation of infiltrating dendritic
cells via NOD1-NOD2-RICK-mediated
pathways.
Whereas PGN in vivo could be from
either the normal mucosal flora or from
infection, adjuvant administration provides
the source of PGN in EAE induction.
Studies with the EAE model have helped
define the sequence of immunopatho-
genic events involved in the development
of autoimmune CNS-directed inflamma-
tory diseases. The development of EAE
can be subdivided into two stages: an initi-
ation stage (activation and expansion of
neuroantigen-reactive CD4+ T lympho-
cytes outside of the CNS) and an effector
stage (recruitment and reactivation of
neuroantigen-reactive CD4+ T lympho-
cytes and subsequent inflammatory
response within CNS) (Figure 1; Steinman,
2001). With this model, Shaw et al. (2011)
showed that NOD1-, NOD2-, RICK-, and
TLR2-deficient mice are resistant to EAE.4 Immunity 34, January 28, 2011 ª2011 ElsevThese results indicate that both the NOD-
RICK and TLR2 pathways are important
for EAE pathogenesis, although different
mechanisms are involved as discussed
below. Importantly, by using incomplete
Freund’s adjuvant containing PGN, the
authors established a critical role for
NOD1, NOD2, and RICK in PGN-depen-
dent EAE progression as well.
During the initiation stage of EAE, in
addition to T cell activation and expan-
sion, APCs produce cytokines to regulate
the differentiation of effector CD4+ T cells,
including Th1 (producing IFN-g and
TNF-a) and Th2 (producing IL-4, IL-5,
and IL-10) subsets of T cells as well as
the newly identified Th17 (producing
IL-17, IL-6, and TNF-a) cell lineage.
Whereas Th2 cells are considered to be
counterinflammatory, both Th1 and Th17
cells can independently induce EAE,
possibly through different mechanisms.
Th17 cells are generated as a discrete
lineage after priming in the presence of
TGF-b and IL-6 and subsequently acquire
encephalitogenicity after expansion in the
presence of IL-23 (Korn et al., 2009). A
previous study reported that TLR2
signaling in CD4+ T cells promotes Th17
cell responses and consequent EAE
pathogenesis. Shaw et al. (2011) clearly
show that the NOD-RICK pathway is notier Inc.required for this initiation stage of EAE,
including MOG-specific Th1 or Th17 cell
development and proliferation in the
periphery. Instead, Shaw et al. (2011)
showed that the NOD-RICK pathway,
but not TLR2, plays a critical role in the
activation of CNS-infiltrating dendritic
cells. Taken together, these studies
suggest that the PGN-initiated innate
immune response regulates CNS inflam-
mation either by directly influencing
T cell polarization by activating TLR2
signaling or by exacerbating the CNS
inflammatory response via activation of
NOD-RICK signaling within CNS-infil-
trating APCs.
A ‘‘two-wave hypothesis’’ has been
proposed for the effector stage of EAE.
After priming in peripheral lymph nodes,
antigen-specific Th1 and Th17 cells traffic
through the choroid plexus into the
subarachnoid space (first wave) (Ransoh-
off, 2009), where they encounter antigen
presented by meningeal APCs and are re-
stimulated to undergo clonal expansion.
As a consequence of productive T cell-
APC interactions, Th1 and Th17 signature
cytokines, including IFN-g and IL-17,
respectively, are expressed and act on
the adjacent CNS tissue to trigger the
second wave of leukocyte infiltration. At
the onset of the second wave, after acti-
vation of the endothelial elements of the
blood-brain barrier, Th1 and Th17 cells
adhere to the endothelium via upregu-
lated adhesion molecules and begin
penetration of the capillary endothelium.
Once the activated lymphocytes have ex-
travasated, they are then reactivated by
their cognate antigens presented by local
APCs in the CNS perivascular space,
leading to the amplification of the inflam-
matory cascade in the CNS. The large
numbers of activated Th1 and Th17 cells
and other inflammatory cells subse-
quently migrate deeper into the white
matter of the CNS parenchyma, resulting
in tissue destruction including demyelin-
ation and, eventually, neurologic deficits.
Through bone marrow transfer experi-
ments, the authors found that RICK in
the hematopoietic compartment plays
a critical role in the development of EAE.
Whereas the NOD-RICK pathway is not
required for the priming of the T cells in
the periphery, MOG-specific Th1 and
Th17 cell accumulation was reduced in
the CNS of RICK-deficient mice 17 days
after EAE immunization. Interestingly, the
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Previewstotal number and activation (as deter-
mined by amount of MHC II expression)
of CD11c+ dendritic cells in the CNS are
reduced in NOD1-, NOD2-, and RICK-
deficient mice 17 days after EAE immuni-
zation, suggesting the importance of the
NOD-RICK pathway in the activation of
CNSdendritic cells during EAE. In support
of this, the CNS-infiltrating APCs from
RICK-deficient mice were impaired in
their ability to polarize Th17 effector cells.
Although DCs are rarely found in healthy
CNS parenchyma, they can be detected
histochemically in vascular-rich areas
such as the meninges and choroid plexus
(Zozulya et al., 2010). Therefore, it is
possible that the NOD-RICK pathway
might play an important role in the activa-
tion of meningeal APCs to promote the
first wave of activation and expansion of
antigen-specific Th1 and Th17 cells in
the subarachnoid space. Numerous
studies indeed unambiguously indicate
the potential relevance of meningeal
APCs for CNS immune surveillance and
autoimmune reactions. However, RICK
deficiency does not affect CNS-infiltrating
dendritic cells, macrophages, and granu-
locytes at an earlier time point (5 days
after immunization). Therefore, the NOD-
RICK pathway might also play a critical
role in the activation of perivascular
APCs to achieve the second wave of acti-
vation and expansion of antigen-specific
Th1 and Th17 cells in the perivascular
space. Interestingly, PGN-containing
APCs were detected around blood
vessels in the brains of MS patients.
Taken together, this study by Shaw et al.
(2011) suggests that NOD-RICK signaling
is important for the activation of APCs in
the CNS, which is critical for the reactiva-
tion and expansion of myelin-specific
T cells. Whether the NOD-RICK signaling
is exclusively restricted to CD11c+ DCs
is an open question, because B cells
andmacrophages are also able to presentantigens in the CNS. Cell-specific RICK-
deficient mice will be essential to resolve
which cell population is serving as the
PGN-activated APC in EAE.
In summary, this study by Shaw et al.
(2011) implies a critical role of PGN-
induced NOD1- and NOD2-mediated
RICK activation in CNS inflammatory
response through its impact on the activa-
tion of peripherally derived CNS APCs
and the consequent effector stage of
EAE. The detection of PGN-containing
APCs in the brains of MS patients indi-
cates the relevance of NOD-RICK
signaling inMS.BecauseRICK is a kinase,
it is attractive to postulate that inhibition
of RICK might offer a novel intervention
for MS. It is intriguing that while RICK
originally was classified as a serine-thero-
nine kinase, a recent study reported
that RICK also has tyrosine kinase activity
(Tigno-Aranjuez et al., 2010). Interest-
ingly, the EGF tyrosine kinase activity
inhibitors gefitinib and erlotinib were
found to inhibit RICK kinase activity and
PGN-induced cytokine responses. It is
important to note that deregulation of
NOD1 and NOD2 signaling impacts on
many forms of autoimmune inflammatory
diseases, including Crohn’s disease,
Blau Syndrome, sarcoidosis, asthma,
and arthritis (Franchi et al., 2009).
Although inhibition of NOD-RICK
signaling should alleviate the autoimmune
diseases caused or augmented by the
activation of RICK (such as MS, sarcoid-
osis, and asthma), the impairment of this
innate immune axis could lead to loss of
barrier function in the gut, paving the
way for the development of inflammatory
bowel diseases. For instance, loss-of-
function NOD2 alleles have already been
found to be genetically associated with
Crohn’s disease. Therefore, drugs specif-
ically targeted to CNS or airway should
offer safer treatments in MS and asthma
patients, respectively. Because RICKImmunityfunctions downstream of both NOD1
and NOD2, it is also critical to pay atten-
tion to the relative contributions of NOD1
and NOD2 in the pathogenesis of
a specific disease, especially for diseases
where NOD1 and NOD2 have opposing
effects (such as with arthritis). Lastly,
because NOD2 loss-of-function polymor-
phisms are present in approximately 7%–
9% of the general population, genetic
studies will help show whether this
subpopulation is genetically more resis-
tant to MS development or progression.
Future studies such as these might help
to reconcile some of the controversial
issues regarding NOD specificity and
mechanisms of action, which may yield
useful information for both the prognosti-
cation of diseases and the development
of inhibitors specific for NOD1 or NOD2.REFERENCES
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